Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

LESK reported for 2023 by RAS

3/26/24 LPSB

Dixie has implemented Imredi OSA digital assistant

3/26/24 MGNT

Ozon will insure the risks of sellers, delivery points and goods

3/26/24 OZON

Mosgorlombard launched wholesale jewelry trading

3/26/24 MGKL

Whoosh opened the season in Moscow

3/26/24 WUSH

Moscow Exchange will launch an autosurveillance service

3/26/24 MOEX

Ozone plans to launch its own insurance company

3/26/24 OZON

Board of Directors of Tattelecom recommended dividends

3/26/24 TTLK

Gazprom buys 27.5% of Sakhalin-2

3/26/24 GAZP

Novatek left without a stake in Sakhalin-2

3/26/24 NVTK